Living between two versions of yourself — one that burns too bright, one that can barely move. The oscillation itself becomes exhausting, and the medications that flatten the peaks also flatten everything else.
Lithium remains the gold standard mood stabilizer after 70 years. Anticonvulsants like valproate and lamotrigine are common alternatives. Atypical antipsychotics — quetiapine, olanzapine, lurasidone — are prescribed for both manic and depressive episodes. Most patients require lifelong medication with regular blood monitoring. Side effect profiles are heavy: weight gain, tremor, thyroid disruption, cognitive dulling. Treatment-resistant bipolar depression remains a significant clinical challenge, with limited options beyond ECT and clozapine.
Sigal et al. (2003) published case reports in the Journal of Clinical Psychopharmacology documenting bipolar patients who experienced significant mood stabilization during HBOT courses prescribed for concurrent medical conditions. The authors proposed that enhanced oxygen delivery to the prefrontal cortex may modulate the neural circuits implicated in mood dysregulation.1
Hadanny et al. (2015) demonstrated in a study published in PLOS ONE that HBOT at 1.5 ATA improved cognitive function and quality of life in patients with brain injuries who had comorbid mood symptoms. Depression and anxiety scores improved significantly, suggesting effects on shared neurobiological pathways with bipolar depression.2
Efrati and Ben-Jacob (2014) reviewed the neuroplasticity mechanisms of HBOT in Expert Review of Neurotherapeutics, demonstrating that mild hyperbaric protocols upregulate BDNF, promote neurogenesis in the hippocampus, and reduce neuroinflammatory markers — all processes implicated in bipolar disorder pathophysiology.3
Cassano et al. (2015) presented evidence in The Journal of Clinical Psychiatry from an open-label trial of transcranial photobiomodulation at 808 nm for bipolar depression. Patients in depressive episodes showed significant reductions in HAM-D depression scores without triggering manic switching — a critical safety consideration for any bipolar treatment.4
Schiffer et al. (2009) demonstrated in Behavioural and Brain Functions that a single session of near-infrared light (810 nm) to the forehead produced lasting improvements in depression and anxiety scores. The mechanism — enhanced prefrontal cortex metabolism via cytochrome c oxidase activation — is relevant to bipolar depression, where prefrontal hypoactivity is well-documented.5
Naeser et al. (2014) published findings in Journal of Neurotrauma showing that transcranial LED therapy at 870 nm improved mood, sleep, and cognitive function in TBI patients with comorbid mood disorders. The study noted no adverse mood destabilization, supporting the safety profile for conditions involving mood cycling.6